ously described protocol (7) . In addition to probing for G-CSF, in selected cases RNA was also probed with cDNA specific for IL-3 and granulocyte/macrophage CSF (GM-CSF) (provided by D. Krumwieh, Behringwerke, Marburg, FRG), M-CSF (provided by P. Ralph, Cetus Corp., Emeryville, CA), and IL-6 (provided by T. Hirano, Osaka University, Osaka, Japan). In addition, RNA obtained from subpopulations of SP CML blood cells was analyzed. In all cases RNA was also hybridized to an a-actin cDNA (kindly provided by R. J. Schwartz, Houston, TX) to control for RNA loading . DNA blotting was performed after restriction endonuclease cutting of DNA derived from bone marrow samples of all 54 patients with the enzymes Hind III, Bgl II, Barn HI, Eco RI as described (8) . As germline control DNA derived from normal bone marrow-derived low density cells was used. All blots were rehybridized to a 2-kb Bgl II/Hind 111 5' bcr probe (kindly provided by C. Bartram, Ulm, FRG) to exclude incomplete digestion or overdigestion and showed rearranged bcr sequences .
Purification of Subsets of Cellsfrom CML Blood. The method of purification of various subpopulations of cells from CML blood has been previously reported (9) involving the use of a panel of mAbs (10) and an immune rosette technique to positively or negatively select for CML blood cell subsets . mAbs used are directed against the following antigens: CD2, CD3, (T cells) Blood. Secretion of the G-CSF protein by PBC-derived leukemic cell subpopulations was assayed in a standard two-layer agar (bacto-agar, Difco Laboratories, Detroit, MI) normal bone marrow day 7 CFU-G assay (10) in the presence or absence of 750 neutralizing U/ml of a mAb to G-CSF (neutralizing concentrations of all anticytokine mAbs used in this study were defined by the manufacturers) . To this end, individual cell fractions of three stable phase CML patients were cultured at 106 cells/ml in Iscove's modified Dulbeccds medium (IMDM) supplemented with 10% FCS . After 48 h of culture, cell-free culture supernatants were harvested and incorporated (15% vol/vol) into a CFU-G assay (9, 10) .
Results and Discussion
Leukemic cells were obtained before chemotherapy in 54 patients with CML, 27 diagnosed as having stable phase disease and 27 with myeloid blastic phase. In leukemic cells of all patients the Philadelphia chromosome (Phi ) abnormality (11) and rearranged c-abl/bcr sequences (12) were detected (not shown). In five of nine patients with acute blastic phase, an additional chromosome abnormality, an isochromosome 17q [i(17q)] disclosed clonal evolution. RNA was extracted from leukemic populations ofbone marrow specimens ofall 54 patients and hybridized to G-CSF-specific cDNA ( Fig. 1) . Accumulation ofG-CSF transcripts was detected in 10 of 27 SP samples ( Fig. 1 A, bottom paneo and in 4 of 27 acute blastic phase samples, two of whom had i(17q) . To define the cell population responsible for the G-CSF synthesis by SP CML cells, a first set ofexperiments was performed analyzing RNA from peripheral blood cells for G-CSF transcripts in comparing with transcripts of G-CSF previously obtained from bone marrow samples . In these experiments (not shown), G-CSF mRNA was also detectable in five peripheral blood-derived leukemic samples offive different samples investigated, thus excluding the possibility of G-CSF synthesis by mesenchymal bone marrow cells . In additional experiments (Fig. 2) , density separation and a panel of mAbs followed by immune rosetting were used to obtain cell subpopulations that were enriched for promyelocytes/myelocytes (>,97 % pure), for mature granulocytes (>99% pure), and for blast cells (>94% pure) by positive and negative selection procedures . G-CSF cDNA that was hybridized to RNA derived from enriched populations failed to detectably hybridize with blast cell-derived RNA. Specific signals, however, appeared when RNA from P/M-eF (giving the strongest signal) and GRAN (giving the weakest signal) were investigated (Fig. 2 B) . Similarly, supernatants of cultures ofblood mononuclear cells and their promyelocyte/myelocyte and granulocyte subpopulations, but not blast cell fractions, displayed biologic activity for G-CSF when tested on purified normal bone marrow-derived granulocyte colony-forming (CFU-G) cells (Fig. 2 A) . To investigate whether maturing leukemic cells producing G-CSF also responded to this factor by stimulating their own growth in an autocrine fashion, SP CML cells enriched for promyelocytes/myelocytes were cultured in semisolid agar in the presence or absence of neutralizing and nonneutralizing mAbs to recombinant human (rh) G-CSF and were investigated for their ability to generate clones . Fig. 3 shows that P/M-eF of CML populations generated up to 60 clones/103 cells over a period of 7 d, which could be inhibited by treating the cultures with neutralizing mAb to G-CSF, thus demonstrating that CML-derived promyelocytes/myelocytes use autocrinously secreted G-CSF to spur their own terminal divisions. It should be noted that anti-G-CSF antibody had no inhibitory effect on clonal growth of CML cultures established with cells not ex- Southern blot analysis of DNA digested with Hind III (A) derived from lowdensity bone marrow cells of two patients (patients 6 and 13) with blastic phase CML probingwith a G-CSF cDNA. (B) DNA blots of DNA from low density bone marrow cells of patient 13 digested with Bgl II, Barn HI, and Eco RI, probed with a G-CSF cDNA (P). As germline control (CO) DNA derived from normal bone marrow low density cells was used . Incomplete digestion or overdigestion was excluded by demonstrating rearranged bcr sequences following rehybridization with a specific probe (not shown) .
pressing the G-CSF gene. Since both SP and BC CML that expressed G-CSF also accumulated transcripts of M-CSF (9 of 14), IL-6 (12 of 14), but not of GM-CSF and IL-3 ( Fig. 1 B) , identical experiments were performed using neutralizing concentrations ofmAbs to rh M-CSF (kindly provided by P Ralph) and to rhIL-6 (kindly provided by T. Hirano). Anti-M-CSF and anti IL-6 mAbs were, however, unable to prevent generation of clones by P/M-eF of SP CML cells. Of the four G-CSF mRNA expressing BC CML samples investigated, only one grew autonomously in agar (patient 13, see Figs . 1 t1, fop panel; and 4, A, B). However, none of the anticytokine mAbs used (anti-G-CSF, -M-CSF, -IL-6) were capable of inhibiting autonomous blast growth, even when used in high concentrations (2,000 neutralizing U/ml) and in combinations (data not shown) .
Normal blood or nonmesenchymal bone marrow cells da not secrete hematopoietic growth factors unless activated (3, 4) ; thus, constitutive expression of G-CSF by CML cells must be ranked as highly abnormal. Recently, rearrangement of the gene for GM-CSF has been shown to result in expression of the GM-CSF gene in some cases ofacute myelogenous leukemia (14) . Therefore, we searched for genomic alterations of the G-CSF, M-CSF, and IL-6 gene in all our patients. Restriction endonuclease analysis and Southern blotting revealed germline configurations of the G-CSF gene for DNA samples of 52 patients and of the M-CSF and IL-6 gene in all 54 patients (data not shown) . Nongermline G-CSF gene-related fragments of variable sizes were, however, detected in two of nine cases of BC CML with i(17q), the chromosome to which the G-CSF gene had been assigned (15) , thus suggesting that the i(17q) may occasionally bear a breakpoint within the G-CSF gene . Further work to analyze this chromosome region is being actively pursued in our laboratory.
Summary
In this paper we demonstrate that maturing neoplastic cells from patients with chronic myelogenous leukemia (CML) constitutively produce G-CSF and are also
